- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 28.03. | Strategic update on the progress and development of Molecure's key clinical projects in 2024 | 235 | GlobeNewswire (Europe) | Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02.... ► Artikel lesen | |
| 15.10.24 | Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. | 332 | GlobeNewswire (Europe) | This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,583 | -1,54 % | Sangamo Therapeutics: Hoch spekulativ, aber mit guten Aussichten auf Kursgewinne! | ||
| IMMATICS | 8,730 | +8,04 % | Immatics Appoints Venkat Ramanan as Chief Financial Officer | Houston, Texas and Tuebingen, Germany, October 1, 2025 - Immatics N.V.as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedInand Instagram.Forward-Looking... ► Artikel lesen | |
| MEDIFAST | 11,880 | -0,21 % | Medifast Bolsters Growth Through Health & Wellness Solutions | ||
| PHARMING | 1,253 | +0,89 % | Pharming Group N.V.: Pharming Group provides update on previously announced G&A expense reduction plan | Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,500 | +1,90 % | Coherus Oncology: Nach der Rallye folgt der Durchbruch? | Die Aktie von Coherus Oncology hat in den vergangenen Monaten deutlich an Dynamik gewonnen. Mit über 60 Prozent Kursplus seit April 2025 rückt das Unternehmen ins Rampenlicht - getragen von wachsenden... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 18,300 | +3,39 % | Oruka Therapeutics files to sell 39.43M shares of common stock for holders | ||
| ARMATA PHARMACEUTICALS | 2,620 | -9,03 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update | Entered into secured credit agreement with Innoviva for $15 million maturing in 2029
Announced positive topline results from the Phase 1b /2a diSArm trial for AP-SA02
... ► Artikel lesen | |
| INNOVIVA | 14,900 | +0,68 % | Innoviva Specialty Therapeutics, Inc.: FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 | FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update | Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025
NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,315 | -1,71 % | SIGA Technologies - A solid quarter for topline growth | Q225 was a strong quarter for SIGA, supported by material topline traction, with deliveries of $79m of oral and IV TPOXX to the US strategic national stockpile (SNS), fully servicing the order book... ► Artikel lesen | |
| DBV TECHNOLOGIES | 2,800 | +13,82 % | DBV Technologies S.A.: DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq | Châtillon, France, October 6, 2025
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
DBV Technologies (Euronext: DBV - ISIN:... ► Artikel lesen | |
| LIQUIDIA | 21,160 | +2,62 % | Liquidia Technologies, Inc.: Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 | ||
| SYNDAX PHARMACEUTICALS | 14,300 | +0,70 % | Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October... ► Artikel lesen | |
| MATINAS BIOPHARMA | 1,860 | -1,06 % | Matinas BioPharma Holdings, Inc. - 8-K, Current Report |
Das Unternehmen MOLECURE SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,012 (+0,68 %) liegt der Kurs bei 1,776 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.